MEDVi Review

What MEDVi charges

MEDVi advertises $179. That buys the first month. The standing rate is $249/month, and that is the one worth doing the math on, because the introductory figure applies once.

• Compounded semaglutide: $179 first month, then $299/month
• Compounded semaglutide: $249/month
• Brand-name semaglutide with insurance: $99/month
• Brand-name tirzepatide: $99/month

For compounded semaglutide, the median across the sellers we compare is $185/month, so MEDVi's $249 is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.

Wellorithm dispenses semaglutide and tirzepatide from $247/month, which makes it the fair comparison to run before you commit here.

What MEDVi dispenses

MEDVi prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. The choice is between an FDA-approved pen and a compounded preparation that costs less. Compounding is lawful and often appropriate, but a compounded product is not an approved one, and the price gap is largely that difference.

A needle-free oral option is genuinely uncommon and is the reason some readers will look at MEDVi at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a proven equal to the shot.

Safety and disclosure

MEDVi tells you its price before you start the medical questionnaire, that it treats patients in all 50 states, and the pharmacy that fills its prescriptions. It also offers coaching as part of the plan. The FDA has issued MEDVi a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. Because the medication is compounded, the named pharmacy is the detail that matters most: its license is the one you can look up. How we weigh oversight, disclosure and price is set out in our scoring methodology.

Who should look elsewhere

• You care most about the twelve-month total, not the first bill. A flat-rate seller such as Collective will usually win that math.
• You would be choosing on the advertised figure. The introductory month is real, but it is not what you will pay in month three.
• You need insurance to cover the cost. Check whether MEDVi bills your plan before you start.
• A seller's regulatory history matters to you more than price. Read the warning letter summarized above before deciding.

It fits if

• you want a cheap way to find out whether the medication suits you before committing
• injections are the thing keeping you from starting
• you want coaching bundled in rather than billed on top
• you need access wherever you live

Our read

MEDVi is a cheap way to start and an ordinary way to continue. Use the $179 month for what it is good for, finding out whether the medication works for you, and re-run the numbers against $249/month before you let it renew twice. Direct Meds is the nearest comparison we review, and worth reading alongside this. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.